吲哚布芬在抗血小板治疗中的临床应用

摘要/Abstract

摘要：

血栓栓塞性疾病严重威胁着人类的生命健康和生活质量，而抗血小板治疗是治疗血栓栓塞性疾病的重要手段，其中吲哚布芬作为一种抗血小板药物，对于治疗及预防血栓栓塞性疾病有一定的疗效。现就吲哚布芬对高危患者血栓栓塞事件的二级预防作用及其他血栓栓塞性疾病的治疗价值，对移植血管或介入术后冠状动脉通畅性的维持作用方面做一综述，以期指导临床。

文章导读： 吲哚布芬作为一种抗血小板药物，对于治疗及预防血栓栓塞性疾病具有一定的疗效，可以作为不能接受一线抗栓方案的患者的替代治疗。

关键词: 吲哚布芬; 血栓栓塞性疾病; 抗血小板

Abstract:

Thromboembolic disease seriously threatens human's life and health and quality of life, and antiplatelet therapy is an important means of treatment for thromboembolic disease. As one kind of antiplatelet agents, indobufen is remarkable in the treatment and prevention for thromboembolic disease. This article summarizes the secondary prevention effects of indobufen for thromboembolic events in patients with high risk, the treatment for other thromboembolic diseases, and the patency maintenance function for grafts or coronary artery after interventions, with the aim to guide the clinical practice.

Key words: Indobufen; Thromboembolic disease; Antiplatelet

吴昊，毕齐. 吲哚布芬在抗血小板治疗中的临床应用[J]. 中国卒中杂志, 2013, 8(09): 773-776.

WU Hao, BI Qi.. Clinical Application of Indobufen in the Treatment of Antiplatelet[J]. Chinese Journal of Stroke, 2013, 8(09): 773-776.

参考文献

1 胡大一, 孙艺红. 贯彻循证医学原则重视血栓栓塞性疾病的防治[J]. 中华医学杂志, 2005:2163-2168.

2 Tamassia V, Corvi G, Fuccella LM, et al. Indobufen (K 3920), a new inhibitor of platelet aggregation:effect of food on bioavailability, pharmacokinetic and pharmacodynamic study during repeated oral administration to man[J]. Eur J Clin Pharmacol, 1979, 15:329-333.

3 Patrono C, Baigent C, Hirsh J, et al. Antiplatelet drugs:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)[J]. Chest, 2008, 133:199S-233S.

4 Battaglia A, Stragliotto E, Heiman F, et al. Indobufen in the secondary prevention of cerebral ischemic attack (TIA):A prospective, randomized, controlled study[J]. Thromb Haemost, 1993, 69:1349-1358.

5 Bergamasco B, Benna P, Carolei A, et al. A randomized trial comparing ticlopidine hydrochloride with indobufen for the prevention of stroke in high-risk patients (TISS Study). Ticlopidine Indobufen Stroke Study[J]. Funct Neurol, 1997, 12:33-43.

6 杨进刚. 心房颤动的诊断与药物治疗(中国专家共识)[J]. 心脑血管病防治, 2008, 8:215-222.

7 Fornaro G, Rossi P, Mantica PG, et al. Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study[J]. Circulation, 1993, 87:162-164.

8 Morocutti C, Amabile G, Fattapposta F, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators[J]. Stroke, 1997, 28:1015-1021.

9 Belcaro G, Errichi BM, De Simone P. Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning[J]. Angiology, 1993, 44:328-331.

10 Cataldo G, Heiman F, Lavezzari M, et al. Indobufen compared with aspirin and dipyridamole on graft patency after coronary artery bypass surgery:results of a combined analysis[J]. Coron Artery Dis, 1998, 9:217-222.

11 Barillà F, Pulcinelli FM, Mangieri E, et al. Clopidogrel plus indobufen in acute coronary syndrome patients with hypersensitivity to aspirin undergoing percutaneous coronary intervention[J]. Platelets, 2013, 24:183-188.

12 温继梨, 崔晓迎. 吲哚布芬应用于PCI术后预防冠状动脉再狭窄的研究[J]. 湖南中医药大学学报, 2012, 32:29-30.

[1]	孟一然, 王卫. 椎动脉残端综合征致后循环反复梗死1例并文献复习[J]. 中国卒中杂志, 2022, 17(12): 1381-1384.
[2]	张亮, 黄立安, 徐安定. CHANCE 2开创了基因指导下卒中抗血小板治疗的先河[J]. 中国卒中杂志, 2022, 17(08): 807-812.
[3]	孔晓彤, 刘佩芳, 蔡涵璐, 王宇, 王丽华. 基于快速CYP2C19基因检测的快代谢型急性轻型缺血性卒中双抗治疗1例报道[J]. 中国卒中杂志, 2022, 17(08): 814-816.
[4]	冯博, 赵彩君, 常立国. 基于快速CYP2C19基因检测发现携带功能缺失等位基因的急性轻型缺血性卒中双抗治疗1例报道[J]. 中国卒中杂志, 2022, 17(08): 817-820.
[5]	中国卒中学会神经介入分会. 症状性颅内动脉粥样硬化性狭窄血管内治疗中国专家共识2022[J]. 中国卒中杂志, 2022, 17(08): 863-888.
[6]	李振华, 刘著, 胡全忠. 非致残性缺血性脑血管事件药物治疗进展[J]. 中国卒中杂志, 2022, 17(04): 407-412.
[7]	王拥军, 熊云云, 李子孝, 张玉梅, 杨晓萌, 王上, 霍晓川, 杨明, 谢雪微, 罗岗, 陈晓霖, 李光硕, 王利圆, 王传颖, 闫然, 王文洁, 段春苗, 路正钊. 卒中：回眸2021[J]. 中国卒中杂志, 2022, 17(01): 1-20.
[8]	张俊良, 黄双凤, 徐璐瑶, 向薇, 张曼曼, 梁志刚. 替罗非班治疗MRI筛选的轻中度非心源性缺血性卒中的安全性和有效性研究[J]. 中国卒中杂志, 2022, 17(01): 66-72.
[9]	赵义. 困局与破局：聚焦大动脉炎并发脑梗死[J]. 中国卒中杂志, 2021, 16(12): 1199-1202.
[10]	王聪杰, 李虹, 郑丽, 刘珊, 卢海丽, 陈娜, 张斌, 周衡. 轻型缺血性卒中静脉溶栓后双重抗血小板疗效观察[J]. 中国卒中杂志, 2021, 16(10): 1044-1049.
[11]	张凤, 武希庆, 冯乐燕, 贾玉勤. 双侧延髓内侧梗死病例报道2例及文献复习[J]. 中国卒中杂志, 2021, 16(10): 1062-1066.
[12]	王璐瑶, 熊云云, 王上. 负荷剂量双联抗血小板治疗后超时间窗无影像错配的急性缺血性卒中患者阿替普酶静脉溶栓1例报告[J]. 中国卒中杂志, 2021, 16(06): 616-618.
[13]	于一娇，刘丽，杜娟，李薇，林甜，路冬煦，蔡艺灵. 内囊预警综合征的临床特征和预后[J]. 中国卒中杂志, 2020, 15(12): 1317-1321.
[14]	马高亭，缪中荣. 抗血小板治疗在血管内治疗缺血性脑血管病中的应用[J]. 中国卒中杂志, 2020, 15(02): 202-208.
[15]	刘丽萍，陈玮琪，段婉莹，等，中国卒中学会中国脑血管病临床管理指南撰写委员会（*第一作者）. 中国脑血管病临床管理指南（节选版）—— 缺血性脑血管病临床管理[J]. 中国卒中杂志, 2019, 14(07): 709-726.